155 related articles for article (PubMed ID: 33953303)
21. A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3).
Möller-Hackbarth K; Dewitz C; Schweigert O; Trad A; Garbers C; Rose-John S; Scheller J
J Biol Chem; 2013 Nov; 288(48):34529-44. PubMed ID: 24121505
[TBL] [Abstract][Full Text] [Related]
22. Different ADAMs have distinct influences on Kit ligand processing: phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by ADAM19.
Kawaguchi N; Horiuchi K; Becherer JD; Toyama Y; Besmer P; Blobel CP
J Cell Sci; 2007 Mar; 120(Pt 6):943-52. PubMed ID: 17344430
[TBL] [Abstract][Full Text] [Related]
23. ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha.
Le Gall SM; Bobé P; Reiss K; Horiuchi K; Niu XD; Lundell D; Gibb DR; Conrad D; Saftig P; Blobel CP
Mol Biol Cell; 2009 Mar; 20(6):1785-94. PubMed ID: 19158376
[TBL] [Abstract][Full Text] [Related]
24. A Disintegrin and Metalloproteinase10 (ADAM10) Regulates NOTCH Signaling during Early Retinal Development.
Toonen JA; Ronchetti A; Sidjanin DJ
PLoS One; 2016; 11(5):e0156184. PubMed ID: 27224017
[TBL] [Abstract][Full Text] [Related]
25. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
[TBL] [Abstract][Full Text] [Related]
26. Substrate-selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains.
Tang B; Li X; Maretzky T; Perez-Aguilar JM; McIlwain D; Xie Y; Zheng Y; Mak TW; Weinstein H; Blobel CP
FASEB J; 2020 Apr; 34(4):4956-4969. PubMed ID: 32103528
[TBL] [Abstract][Full Text] [Related]
27. Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.
Araya HF; Sepulveda H; Lizama CO; Vega OA; Jerez S; Briceño PF; Thaler R; Riester SM; Antonelli M; Salazar-Onfray F; Rodríguez JP; Moreno RD; Montecino M; Charbonneau M; Dubois CM; Stein GS; van Wijnen AJ; Galindo MA
J Cell Biochem; 2018 Nov; 119(10):8204-8219. PubMed ID: 29923217
[TBL] [Abstract][Full Text] [Related]
28. Structural modeling defines transmembrane residues in ADAM17 that are crucial for Rhbdf2-ADAM17-dependent proteolysis.
Li X; Maretzky T; Perez-Aguilar JM; Monette S; Weskamp G; Le Gall S; Beutler B; Weinstein H; Blobel CP
J Cell Sci; 2017 Mar; 130(5):868-878. PubMed ID: 28104813
[TBL] [Abstract][Full Text] [Related]
29. Genetic variants of ADAM17 are implicated in the pathological process of Kawasaki disease and secondary coronary artery lesions via the TGF-β/SMAD3 signaling pathway.
Peng Q; Deng Y; Yang X; Leng X; Yang Y; Liu H
Eur J Pediatr; 2016 May; 175(5):705-13. PubMed ID: 26833052
[TBL] [Abstract][Full Text] [Related]
30. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules.
Ludwig A; Hundhausen C; Lambert MH; Broadway N; Andrews RC; Bickett DM; Leesnitzer MA; Becherer JD
Comb Chem High Throughput Screen; 2005 Mar; 8(2):161-71. PubMed ID: 15777180
[TBL] [Abstract][Full Text] [Related]
31. Leukocytes require ADAM10 but not ADAM17 for their migration and inflammatory recruitment into the alveolar space.
Pruessmeyer J; Hess FM; Alert H; Groth E; Pasqualon T; Schwarz N; Nyamoya S; Kollert J; van der Vorst E; Donners M; Martin C; Uhlig S; Saftig P; Dreymueller D; Ludwig A
Blood; 2014 Jun; 123(26):4077-88. PubMed ID: 24833351
[TBL] [Abstract][Full Text] [Related]
32. Construction of a lentiviral vector containing shRNA targeting ADAM17 and its role in attenuating endotoxemia in mice.
He B; Li X; Hu T; Lian W; Zhang M
Mol Med Rep; 2017 Nov; 16(5):6013-6019. PubMed ID: 28849138
[TBL] [Abstract][Full Text] [Related]
33. Disturbed follicular architecture in B cell A disintegrin and metalloproteinase (ADAM)10 knockouts is mediated by compensatory increases in ADAM17 and TNF-α shedding.
Folgosa L; Zellner HB; El Shikh ME; Conrad DH
J Immunol; 2013 Dec; 191(12):5951-8. PubMed ID: 24227779
[TBL] [Abstract][Full Text] [Related]
34. The Gut-Brain Axis in Autism Spectrum Disorder: A Focus on the Metalloproteases ADAM10 and ADAM17.
Zheng Y; Verhoeff TA; Perez Pardo P; Garssen J; Kraneveld AD
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374371
[TBL] [Abstract][Full Text] [Related]
35. Functional Characterization of Colon Cancer-Associated Mutations in
Pavlenko E; Cabron AS; Arnold P; Dobert JP; Rose-John S; Zunke F
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31060243
[TBL] [Abstract][Full Text] [Related]
36. The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II.
Lorenzen I; Lokau J; Düsterhöft S; Trad A; Garbers C; Scheller J; Rose-John S; Grötzinger J
FEBS Lett; 2012 Apr; 586(8):1093-100. PubMed ID: 22575642
[TBL] [Abstract][Full Text] [Related]
37. ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranes.
Condon TP; Flournoy S; Sawyer GJ; Baker BF; Kishimoto TK; Bennett CF
Antisense Nucleic Acid Drug Dev; 2001 Apr; 11(2):107-16. PubMed ID: 11334139
[TBL] [Abstract][Full Text] [Related]
38. Molecular switch in human diseases-disintegrin and metalloproteinases, ADAM17.
Yang G; Cui M; Jiang W; Sheng J; Yang Y; Zhang X
Aging (Albany NY); 2021 Jun; 13(12):16859-16872. PubMed ID: 34182543
[TBL] [Abstract][Full Text] [Related]
39. Association Study Between Promoter Polymorphisms of ADAM17 and Progression of Sepsis.
Shao Y; He J; Chen F; Cai Y; Zhao J; Lin Y; Yin Z; Tao H; Shao X; Huang P; Yin M; Zhang W; Liu Z; Cui L
Cell Physiol Biochem; 2016; 39(4):1247-61. PubMed ID: 27607600
[TBL] [Abstract][Full Text] [Related]
40. Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease.
Kubo S; Fritz JM; Raquer-McKay HM; Kataria R; Vujkovic-Cvijin I; Al-Shaibi A; Yao Y; Zheng L; Zou J; Waldman AD; Jing X; Farley TK; Park AY; Oler AJ; Charles AK; Makhlouf M; AbouMoussa EH; Hasnah R; Saraiva LR; Ganesan S; Al-Subaiey AA; Matthews H; Flano E; Lee HH; Freeman AF; Sefer AP; Sayar E; Çakır E; Karakoc-Aydiner E; Baris S; Belkaid Y; Ozen A; Lo B; Lenardo MJ
Nat Immunol; 2022 Jan; 23(1):75-85. PubMed ID: 34937930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
